联系我们

论文查询结果	返回搜索

论文编号：	15812
作者编号：	2320213688
上传时间：	2025/12/10 13:52:36
中文题目：	C公司新型疫苗流通管理优化研究
英文题目：	Research on the Optimization of Innovative Vaccine Distribution Management of Company C
指导老师：	李凯教授
中文关键字：	创新性疫苗；流通管理；服务模式；供应链管理
英文关键字：	innovative vaccine; distribution channels; service model; supply chain management
中文摘要：	疫苗流通作为公共卫生防控体系的关键环节，其效率与安全性直接影响疾病防治成效。新冠疫情爆发后，创新性疫苗因研发周期短、技术壁垒高、冷链存储运输要求严苛等特点，使传统流通模式面临政企协同不畅、供应链适配不足、监管标准不统一等诸多挑战。在此背景下，本文以C公司创新疫苗为研究对象，围绕创新性疫苗流通管理优化展开研究。 本文依托供应链管理相关理论、药品监管相关理论及利益相关者理论，综合运用文献研究法、问卷调查法与深度访谈法，系统梳理C公司创新疫苗流通现状，分析存在的主要问题，并且给出合理的策略。研究发现，C公司创新疫苗流通当中，目前主要形成了政企协同试点采购、“疫苗+雾化设备”组合配送、第三方冷链物流外包、疾控系统定向终端服务四种模式，在应急供应中发挥了重要作用，但仍存在突出问题，包括：试点采购缺乏长效政企对接机制导致流程适配性差、“疫苗—设备”供应链协同不足影响配送效率、第三方冷链物流准入管控与服务标准不匹配存在安全隐患、疾控终端培训及响应机制薄弱制约服务质量。问题根源在于流通战略与协同机制滞后、供应链管理体系适配性欠缺、外包管控体系缺失及终端资源投入不足。据此，本文提出建立政企协同长效采购机制、构建“疫苗—设备”供应链协同配送体系、完善第三方冷链物流监管标准、强化疾控终端服务能力等优化措施，并从组织、资源、制度、技术四维度设计保障方案。 本研究聚焦企业微观实践，丰富了创新性疫苗流通微观实证研究，通过融合三大理论构建整合框架实现理论与研究对象的精准适配，针对组合流通、政企协同、冷链监管、终端服务等核心痛点提出闭环优化方案，突破传统模式局限。可为创新性疫苗流通效率提升与风险管控提供实践指引，也为企业运营及监管部门决策提供参考。
英文摘要：	As a critical component of public health prevention and control systems, the efficiency and safety of vaccine distribution directly impact disease prevention outcomes. Following the COVID-19 outbreak, innovative vaccines—characterized by short development cycles, high technical barriers, and stringent cold chain storage requirements have posed multiple challenges to traditional distribution models, including inadequate government-enterprise coordination, supply chain incompatibility, and inconsistent regulatory standards. This study focuses on Company C's innovative vaccine distribution system to optimize its operational approaches. Grounded in supply chain management theory, pharmaceutical regulatory frameworks, and stakeholder analysis, we employ literature review, questionnaire surveys, and in-depth interviews to systematically examine Company C's current distribution practices. The findings reveal four primary operational models: government-enterprise pilot procurement programs, "vaccine + nebulization equipment" integrated distribution systems, third party logistics outsourcing, and targeted terminal services through disease control systems. While these models have played significant roles in emergency supply, persistent issues remain: the lack of sustainable government-enterprise coordination mechanisms leads to operational mismatches, insufficient "vaccine-device" supply chain collaboration hampers delivery efficiency, inconsistent third party logistics standards create safety risks, and inadequate terminal training and response mechanisms compromise service quality. Root causes include outdated distribution strategies, mismatched supply chain management systems, absence of outsourcing control mechanisms, and insufficient terminal resource allocation. Based on this, the paper proposes optimization measures including establishing a long-term government-enterprise collaborative procurement mechanism, building a "vaccine-device" supply chain collaborative distribution system, improving third-party cold chain logistics supervision standards, and enhancing disease control terminal service capabilities. It designs safeguard solutions from four dimensions: organization, resources, systems, and technology. The study provides practical guidance for improving the efficiency of innovative vaccine distribution and risk management, while offering references for corporate operations and regulatory decision making. This study focuses on enterprise-level micro-practices, enriching the empirical research on innovative vaccine distribution. By integrating three major theories to construct a unified framework, it achieves precise alignment between theoretical models and practical research subjects. The research proposes closed-loop optimization solutions targeting core pain points such as combined distribution channels, government-enterprise collaboration, cold chain supervision, and terminal services, thereby breaking through the limitations of traditional models. The findings provide practical guidance for enhancing the efficiency of innovative vaccine distribution and risk management, while also offering valuable references for corporate operations and regulatory decision-making.
查看全文：	预览  下载(下载需要进行登录)